Aurinia bets on doing one thing well: selling Lupkynis for a serious kidney complication of lupus, with signs that doctor use and insurance coverage are settling into a steadier rhythm. The key question is whether that focus can keep working as competition and pricing pressure build, and as the company looks abroad for its next leg of growth.Read more